Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Michael Grundman

Title(s)Adjunct Professor, Neurosciences
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Low-dose interleukin-2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trial. Alzheimers Res Ther. 2025 Jul 04; 17(1):146. Faridar A, Gamez N, Li D, Wang Y, Boradia R, Thome AD, Zhao W, Beers DR, Thonhoff JR, Nakawah MO, Román GC, Volpi JJ, Toledo JB, George M, Davis CS, Pascual B, Grundman M, Masdeu JC, Appel SH. PMID: 40615880; PMCID: PMC12231701.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    2. Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812. Alzheimers Dement (N Y). 2025 Apr-Jun; 11(2):e70119. Di Caro V, Cho E, North HA, Caldwell J, Pandey K, Duong D, Grundman M, de Haan W, Vijverberg EG, Teunissen CE, Caggiano AO, Seyfried NT, Hamby ME. PMID: 40547328; PMCID: PMC12178945.
      View in: PubMed   Mentions:
    3. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 01; 82(1):19-29. Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R. PMID: 39556389; PMCID: PMC11574721.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    4. Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation. J Prev Alzheimers Dis. 2025 Jan; 12(1):100001. Cummings J, Gold M, Mintun M, Irizarry M, von Eschenbach A, Hendrix S, Berry D, Sampaio C, Sink K, Landen J, Kivipelto M, Grundman M, Arnold SE, Green A, Partrick K, Nisenbaum L, Burstein A, Fillit H. PMID: 39800453; PMCID: PMC12183988.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    5. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimers Dement. 2024 Oct; 20(10):6860-6880. Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME. PMID: 39166791; PMCID: PMC11485314.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    6. Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease. EClinicalMedicine. 2024 Jul; 73:102693. Wise-Brown A, Brangman SA, Henderson JN, Willis-Parker M, Monroe S, Mintzer JE, Grundman M, Smith J, Doody RS, Lin H, Assman B, Rippon GA, Gonzales R, Assunção SS. PMID: 39429811; PMCID: PMC11490654.
      View in: PubMed   Mentions: 5  
    7. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease. Neurobiol Dis. 2024 09; 199:106575. Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, Di Caro V, Ping L, Blennow K, Zetterberg H, Lah J, Levey AI, Grundman M, Caggiano AO, Seyfried NT, Hamby ME. PMID: 38914170.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    8. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease. Alzheimers Res Ther. 2024 01 25; 16(1):20. van Dyck CH, Mecca AP, O'Dell RS, Bartlett HH, Diepenbrock NG, Huang Y, Hamby ME, Grundman M, Catalano SM, Caggiano AO, Carson RE. PMID: 38273408; PMCID: PMC10809445.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCTClinical Trials
    9. A Pilot Electroencephalography Study of the Effect of CT1812 Treatment on Synaptic Activity in Patients with Mild to Moderate Alzheimer's Disease. J Prev Alzheimers Dis. 2024; 11(6):1809-1817. Vijverberg E, de Haan W, Scheijbeler E, Hamby ME, Catalano S, Scheltens P, Grundman M, Caggiano AO. PMID: 39559892; PMCID: PMC11573871.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    10. A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease. Transl Neurodegener. 2023 11 16; 12(1):54. Faridar A, Eid AM, Thome AD, Zhao W, Beers DR, Pascual MB, Nakawah MO, Roman GC, Davis CS, Grundman M, Masdeu JC, Appel SH. PMID: 37968718; PMCID: PMC10652426.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    11. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2023 Nov; 29(11):2955-2956. Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB, PASSPORT Study Group. PMID: 36253611.
      View in: PubMed   Mentions:    Fields:    
    12. A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter. Transl Neurodegener. 2023 05 12; 12(1):24. LaBarbera KM, Sheline YI, Izzo NJ, Yuede CM, Waybright L, Yurko R, Edwards HM, Gardiner WD, Blennow K, Zetterberg H, Börjesson-Hanson A, Morgan R, Davis CS, Guttendorf RJ, Schneider LS, DeKosky S, LeVine H, Grundman M, Caggiano AO, Cirrito JR, Catalano SM, Hamby ME. PMID: 37173791; PMCID: PMC10176668.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    13. Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases. Int J Mol Sci. 2023 Mar 26; 24(7). Lizama BN, Kahle J, Catalano SM, Caggiano AO, Grundman M, Hamby ME. PMID: 37047224; PMCID: PMC10093856.
      View in: PubMed   Mentions: 17     Fields:    Translation:Animals
    14. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021 08; 27(8):1451-1457. Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB, PASSPORT Study Group. PMID: 34385707.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    15. Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology. 2021 05 18; 96(20):944-954. Friedman LG, McKeehan N, Hara Y, Cummings JL, Matthews DC, Zhu J, Mohs RC, Wang D, Hendrix SB, Quintana M, Schneider LS, Grundman M, Dickson SP, Feldman HH, Jaeger J, Finger EC, Ryan JM, Niehoff D, Dickinson SL, Markowitz JT, Owen M, Travaglia A, Fillit HM. PMID: 33674360; PMCID: PMC8205472.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimers Dement. 2021 08; 17(8):1365-1382. Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, Waybright L, Look G, Rishton G, Safferstein H, Hamby ME, Williams C, Sadlek K, Edwards HM, Davis CS, Grundman M, Schneider LS, DeKosky ST, Chelsky D, Pike I, Henstridge C, Blennow K, Zetterberg H, LeVine H, Spires-Jones TL, Cirrito JR, Catalano SM. PMID: 33559354; PMCID: PMC8349378.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    17. The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimers Res Ther. 2020 03 02; 12(1):21. Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM, Synaptic Health Endpoints Working Group. PMID: 32122400; PMCID: PMC7053087.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCells
    18. Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review. J Alzheimers Dis. 2020; 77(3):1181-1194. Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H. PMID: 32925028; PMCID: PMC7683079.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    19. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558. Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T. PMID: 31122495.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    20. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimers Dement (N Y). 2019; 5:20-26. Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM. PMID: 30723776; PMCID: PMC6352291.
      View in: PubMed   Mentions: 52  
    21. Editorial: Tau Based Therapeutics: Alternative Approaches in the War on Alzheimer's Disease. J Prev Alzheimers Dis. 2019; 6(3):151-152. Grundman M. PMID: 31062822.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease. J Prev Alzheimers Dis. 2019; 6(4):228-231. Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, Marek K, Gray M, Hefti F. PMID: 31686093.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    23. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement (N Y). 2018; 4:746-755. Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M. PMID: 30581980; PMCID: PMC6298197.
      View in: PubMed   Mentions: 42  
    24. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 10 01; 75(10):1206-1214. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG. PMID: 29913017; PMCID: PMC6233845.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCTClinical Trials
    25. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Mov Disord. 2018 08; 33(8):1287-1297. Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, Cheng WY, Fernandez-Garcia I, Siebourg-Polster J, Jin L, Soto J, Verselis L, Boess F, Koller M, Grundman M, Monsch AU, Postuma RB, Ghosh A, Kremer T, Czech C, Gossens C, Lindemann M. PMID: 29701258; PMCID: PMC6175318.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCTClinical Trials
    26. Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dement Geriatr Cogn Disord. 2017; 44(3-4):129-143. Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, Salloway S, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD, Mintun MA. PMID: 28787712; PMCID: PMC5806476.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    27. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. J Prev Alzheimers Dis. 2017; 4(2):116-124. Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B. PMID: 29186281; PMCID: PMC5724787.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    28. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017 02; 32(2):211-218. Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG. PMID: 27886407; PMCID: PMC5324684.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCTClinical Trials
    29. Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria. Dement Geriatr Cogn Disord. 2016; 41(1-2):80-92. Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ, 18F-AV-45-A17 Study Group. PMID: 26745445; PMCID: PMC6625826.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    30. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. J Alzheimers Dis. 2016; 49(4):1123-34. Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K, Di J, Collins P, Wyman BT, Yuen E, Grundman M, Brashear HR, Liu E. PMID: 26639957.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    31. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015 Aug 25; 85(8):692-700. Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR, Bapineuzumab 301 and 302 Clinical Trial Investigators. PMID: 26208959; PMCID: PMC4553028.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    32. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools? Alzheimers Dement. 2014 Nov; 10(6):853-60. Snyder PJ, Kahle-Wrobleski K, Brannan S, Miller DS, Schindler RJ, DeSanti S, Ryan JM, Morrison G, Grundman M, Chandler J, Caselli RJ, Isaac M, Bain L, Carrillo MC. PMID: 25458309.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    33. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014 Sep; 19(9):1044-51. Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A11 Study Group, AV45-A11 Study Group. PMID: 24614494; PMCID: PMC4195975.
      View in: PubMed   Mentions: 109     Fields:    Translation:Humans
    34. Cognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB. Clin Neuropsychol. 2014; 28(2):252-68. Harrison J, Rentz DM, McLaughlin T, Niecko T, Gregg KM, Black RS, Buchanan J, Liu E, Grundman M, ELN-AIP-901 Study Investigator Group. PMID: 24521259.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    35. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):322-33. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab 301 and 302 Clinical Trial Investigators. PMID: 24450891; PMCID: PMC4159618.
      View in: PubMed   Mentions: 893     Fields:    Translation:HumansCellsCTClinical Trials
    36. Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany. Qual Life Res. 2014 Aug; 23(6):1813-21. Hauber AB, Mohamed AF, Johnson FR, Cook M, Arrighi HM, Zhang J, Grundman M. PMID: 24448684.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    37. Alzheimer's Disease Drug Development: Trial-Ready Cohorts Should Help. J Prev Alzheimers Dis. 2014; 1(2):69-70. Grundman M. PMID: 29255833.
      View in: PubMed   Mentions: 1     Fields:    
    38. Association between illness progression measures and total cost in Alzheimer's disease. J Nutr Health Aging. 2013 Sep; 17(9):745-50. Lacey LA, Niecko T, Leibman C, Liu E, Grundman M, ELN-AIP-901 Investigator Group. PMID: 24154646.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    39. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P, EU/US/CTAD Task Force Members. PMID: 23809364.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    40. MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol. 2013 Oct; 34(10):1958-65. Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melançon D, Miaux Y, Rippon G, Black R, Lu Y, Brashear HR, Arrighi HM, Morris KA, Grundman M. PMID: 23578674; PMCID: PMC7965435.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    41. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013 Jan-Mar; 27(1):4-15. Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA, 45-A17 Study Group. PMID: 23203162.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    42. 2012: A watershed year for Alzheimer's disease research. J Nutr Health Aging. 2013 Jan; 17(1):51-3. Grundman M, Dibernardo A, Raghavan N, Krams M, Yuen E. PMID: 23299380.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. Improving Alzheimer's disease phase II clinical trials. Alzheimers Dement. 2013 Jan; 9(1):39-49. Greenberg BD, Carrillo MC, Ryan JM, Gold M, Gallagher K, Grundman M, Berman RM, Ashwood T, Siemers ER. PMID: 23164548.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    44. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement. 2013 Feb; 9(1 Suppl):S21-31. Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, Narayan V, DiBernardo A, Alzheimer’s Disease Neuroimaging Initiative. PMID: 23127469; PMCID: PMC3732822.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    45. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013 Mar; 34(3):822-31. Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, Sadowsky CH, Carpenter A, Davis MD, Lu M, Flitter M, Joshi AD, Clark CM, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A05 Study Group. PMID: 22878163; PMCID: PMC3518678.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    46. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012 Aug; 69(8):1002-10. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, AAB-001 201/202 Investigators. PMID: 22473769.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    47. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012 Oct 16; 79(16):1636-44. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A11 Study Group. PMID: 22786606; PMCID: PMC3468774.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    48. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers Dement. 2013 Feb; 9(1 Suppl):S45-55. Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B, Alzheimer's Disease Neuroimaging Initiative. PMID: 22658286.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    49. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. J Nutr Health Aging. 2012 Apr; 16(4):339-45. Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P, Task Force Participants. PMID: 22499454.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    50. Is there a rationale for including only patients already being treated with acetylcholinesterase inhibitors in a prodromal AD trial? J Nutr Health Aging. 2012 Apr; 16(4):336-8. Grundman M, Yang E, Dibernardo A. PMID: 22499453.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012 Mar; 11(3):241-9. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. PMID: 22305802; PMCID: PMC4063417.
      View in: PubMed   Mentions: 251     Fields:    Translation:Humans
    52. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011 Jul; 7(4):367-85. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. PMID: 21784348; PMCID: PMC3693547.
      View in: PubMed   Mentions: 389     Fields:    Translation:HumansAnimals
    53. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. PMID: 21178097; PMCID: PMC3034393.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    54. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):198-203. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M. PMID: 20505438; PMCID: PMC3715117.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    55. Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease. J Nutr Health Aging. 2010 Apr; 14(4):306-9. Cedarbaum JM, Crans G, Grundman M. PMID: 20306002.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    56. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ. PMID: 20298968; PMCID: PMC4298995.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    57. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010 Apr; 9(4):363-72. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. PMID: 20189881.
      View in: PubMed   Mentions: 328     Fields:    Translation:HumansCTClinical Trials
    58. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators. PMID: 19923550; PMCID: PMC2790221.
      View in: PubMed   Mentions: 310     Fields:    Translation:HumansCTClinical Trials
    59. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009 Jul; 30(7):1026-36. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. PMID: 19376612; PMCID: PMC2737680.
      View in: PubMed   Mentions: 365     Fields:    Translation:HumansCells
    60. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res. 2009 Apr; 6(2):144-51. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M, AN1792 (QS-21)-251 Study Team. PMID: 19355849; PMCID: PMC2825665.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    61. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. PMID: 19328434; PMCID: PMC3959165.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    62. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis. 2009; 17(2):243. Ryan JM, Grundman M. PMID: 19502708.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    63. Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease. Alzheimer Dis Assoc Disord. 2009 Jan-Mar; 23(1):23-32. Hauber AB, Johnson FR, Fillit H, Mohamed AF, Leibman C, Arrighi HM, Grundman M, Townsend RJ. PMID: 18725862.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    64. An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease. Neurology. 2008 Aug 26; 71(9):697; author reply 697-8. Grundman M, Gilman S, Black RS, Fox NC, Koller M. PMID: 18725601.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. PMID: 18631960; PMCID: PMC2544623.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    66. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis. 2008; 5(3-4):194-6. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. PMID: 18322388.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimals
    67. A quarter century of advancing treatment for Alzheimer's disease with Leon J. Thal. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S51-5. Grundman M. PMID: 18632001.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007 Sep; 64(9):1323-9. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. PMID: 17846273.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    69. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95. Jack CR, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ, Members of the Alzheimer's Disease Cooperative Study (ADCS). PMID: 17452062; PMCID: PMC2768818.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    70. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007 Jan; 64(1):108-15. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR, Scheltens P, Alzheimer's Disease Cooperative Study Group. PMID: 17210817.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    71. Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned? Alzheimers Dement. 2006 Jul; 2(3):220-33. Grundman M, Petersen RC, Bennett DA, Feldman HH, Salloway S, Visser PJ, Thal LJ, Schenk D, Khachaturian Z, Thies W, Alzheimer's Association Research Roundtable. PMID: 19595891.
      View in: PubMed   Mentions: 10     Fields:    
    72. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005 Jun; 62(6):953-7. Fleisher A, Grundman M, Jack CR, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 15956166.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    73. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 09; 352(23):2379-88. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Group. PMID: 15829527.
      View in: PubMed   Mentions: 647     Fields:    Translation:HumansCTClinical Trials
    74. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis. 2005; 2(5):255-60. Schenk DB, Seubert P, Grundman M, Black R. PMID: 16909006.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsPHPublic Health
    75. Weight loss in the elderly may be a sign of impending dementia. Arch Neurol. 2005 Jan; 62(1):20-2. Grundman M. PMID: 15642845.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    76. Neurological sequelae of Crohn's disease: opportunity to study common etiological pathways. J Gastroenterol Hepatol. 2004 Sep; 19(9):1093-4. Karajeh MA, Hadjivassiliou M, Hurlstone P, Grundman MJ. PMID: 15304135.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 14732621.
      View in: PubMed   Mentions: 342     Fields:    Translation:HumansCTClinical Trials
    78. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology. 2003 Dec 09; 61(11):1498-502. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG. PMID: 14663031.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    79. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003 Nov 01; 26(7):893-901. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 14655926; PMCID: PMC4418658.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansCTClinical Trials
    80. Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients. J Alzheimers Dis. 2003 Oct; 5(5):375-82. Ji M, Xiong C, Grundman M. PMID: 14646028.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    81. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci. 2003 Jun 20; 73(5):539-53. Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 12770610.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    82. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 04; 289(21):2819-26. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 12783912.
      View in: PubMed   Mentions: 344     Fields:    Translation:HumansCTClinical Trials
    83. NSAIDs and hypertension. Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. Aisen PS, Schafer K, Grundman M, Thomas R, Thal LJ. PMID: 12742818.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    84. Estrogen levels do not correlate with improvement in cognition. Arch Neurol. 2003 Feb; 60(2):209-12. Thal LJ, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. PMID: 12580705.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    85. Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci. 2003; 20(3):241-8. Grundman M, Jack CR, Petersen RC, Kim HT, Taylor C, Datvian M, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Darvesh S, Yaffe K, Kaye J, Ferris SH, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 14501003.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    86. Laboratory investigations and treatment in frontotemporal dementia. Ann Neurol. 2003; 54 Suppl 5:S32-5. Pasquier F, Fukui T, Sarazin M, Pijnenburg Y, Diehl J, Grundman M, Miller BL. PMID: 12833367.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    87. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002 Aug-Oct; 19(1-2):23-7. Grundman M, Sencakova D, Jack CR, Petersen RC, Kim HT, Schultz A, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 12212787.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    88. A phase I study of AIT-082 in healthy elderly volunteers. J Mol Neurosci. 2002 Jun; 18(3):283-93. Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mobs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 12059047.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    89. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc. 2002 May; 61(2):191-202. Grundman M, Grundman M, Delaney P. PMID: 12133201.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    90. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000 Nov 14; 55(9):1271-8. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ, Alzheimer's Disease Cooperative Study. PMID: 11087767.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCTClinical Trials
    91. Treatment of Alzheimer's disease: rationale and strategies. Neurol Clin. 2000 Nov; 18(4):807-28. Grundman M, Thal LJ. PMID: 11072262.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    92. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23; 283(8):1007-15. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. PMID: 10697060.
      View in: PubMed   Mentions: 208     Fields:    Translation:HumansCTClinical Trials
    93. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000 Feb 08; 54(3):588-93. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. PMID: 10680787.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCTClinical Trials
    94. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr. 2000 Feb; 71(2):630S-636S. Grundman M. PMID: 10681271.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    95. Prevalence of symptoms on the CERAD behavior rating scale for dementia in normal elderly subjects and Alzheimer's disease patients. J Neuropsychiatry Clin Neurosci. 2000; 12(4):472-9. Tractenberg RE, Patterson M, Weiner MF, Teri L, Grundman M, Thomas RG, Thal LJ. PMID: 11083164.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    96. Assessment of agitation in Alzheimer's disease: the agitated behavior in dementia scale. Alzheimer's Disease Cooperative Study. J Am Geriatr Soc. 1999 Nov; 47(11):1354-8. Logsdon RG, Teri L, Weiner MF, Gibbons LE, Raskind M, Peskind E, Grundman M, Koss E, Thomas RG, Thal LJ. PMID: 10573447.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    97. Mini-Mental State Examination and Mattis Dementia Rating Scale performance differs in Hispanic and non-Hispanic Alzheimer's disease patients. J Int Neuropsychol Soc. 1999 May; 5(4):301-7. Hohl U, Grundman M, Salmon DP, Thomas RG, Thal LJ. PMID: 10349293.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    98. Nursing home placement is related to dementia progression: experience from a clinical trial. Alzheimer's Disease Cooperative Study. Neurology. 1999 Mar 10; 52(4):714-8. Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M. PMID: 10078715.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    99. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J Neural Transm Suppl. 1998; 53:255-75. Grundman M, Corey-Bloom J, Thal LJ. PMID: 9700663.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    100. The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Neurology. 1997 Jul; 49(1):76-81. Olichney JM, Sabbagh MN, Hofstetter CR, Galasko D, Grundman M, Katzman R, Thal LJ. PMID: 9222173.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    101. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997 Apr 24; 336(17):1216-22. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. PMID: 9110909.
      View in: PubMed   Mentions: 490     Fields:    Translation:HumansCTClinical Trials
    102. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S1-12. Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ. PMID: 9236947.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    103. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S45-50. Koss E, Weiner M, Ernesto C, Cohen-Mansfield J, Ferris SH, Grundman M, Schafer K, Sano M, Thal LJ, Thomas R, Whitehouse PJ. PMID: 9236952.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    104. The Spanish Instrument Protocol: design and implementation of a study to evaluate treatment efficacy Instruments for Spanish-speaking patients with Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S57-64. Sano M, Mackell JA, Ponton M, Ferreira P, Wilson J, Pawluczyk S, Pfeiffer E, Thomas RG, Jin S, Schafer K, Schittini M, Grundman M, Ferris SH, Thal LJ. PMID: 9236954.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    105. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S22-32. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. PMID: 9236949.
      View in: PubMed   Mentions: 213     Fields:    Translation:HumansCTClinical Trials
    106. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S33-9. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. PMID: 9236950.
      View in: PubMed   Mentions: 491     Fields:    Translation:HumansCTClinical Trials
    107. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S13-21. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ. PMID: 9236948.
      View in: PubMed   Mentions: 338     Fields:    Translation:Humans
    108. Neurological complications of celiac disease: a rare but continuing problem. Am J Gastroenterol. 1996 Jul; 91(7):1430-5. Muller AF, Donnelly MT, Smith CM, Grundman MJ, Holmes GK, Toghill PJ. PMID: 8678009.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    109. Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. Neurology. 1996 Jun; 46(6):1585-91. Grundman M, Corey-Bloom J, Jernigan T, Archibald S, Thal LJ. PMID: 8649553.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    110. The open ring. A new imaging sign in demyelinating disease. J Neuroimaging. 1996 Apr; 6(2):104-7. Masdeu JC, Moreira J, Trasi S, Visintainer P, Cavaliere R, Grundman M. PMID: 8634482.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    111. Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1996; 10(3):132-40. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ. PMID: 8876776.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    112. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol. 1995 Jul; 52(7):702-8. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ. PMID: 7619027.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    113. Early single-photon emission computed tomography in mild head trauma. A controlled study. J Neuroimaging. 1994 Oct; 4(4):177-81. Masdeu JC, Van Heertum RL, Kleiman A, Anselmi G, Kissane K, Horng J, Yudd A, Luck D, Grundman M. PMID: 7949553.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    114. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry. 1991 Nov; 148(11):1558-61. Hriso E, Kuhn T, Masdeu JC, Grundman M. PMID: 1681751.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    115. Single-photon emission computed tomography in human immunodeficiency virus encephalopathy: a preliminary report. J Nucl Med. 1991 Aug; 32(8):1471-5. Masdeu JC, Yudd A, Van Heertum RL, Grundman M, Hriso E, O'Connell RA, Luck D, Camli U, King LN. PMID: 1869964.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    116. Dementia: characteristics of a referral population and factors associated with progression. Neurology. 1988 Jul; 38(7):1083-90. Thal LJ, Grundman M, Klauber MR. PMID: 3386827.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    117. Alzheimer's disease: a correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam. Neurology. 1986 Feb; 36(2):262-4. Thal LJ, Grundman M, Golden R. PMID: 3945395.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    118. A controlled trial of disodium cromoglycate in the treatment of Crohn's disease. Digestion. 1980; 20(6):395-8. Williams SE, Grundman MJ, Baker RD, Turnberg LA. PMID: 6773843.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    Michael's Networks
    Concepts (323)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (34)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California